Ácido Valpróico:

revisão

Autores

  • Sayonara Beatriz Ranciaro Fagundes Médica associada e pesquisadora do Neuroinstituto Forel e Especializanda UNIFESP.

DOI:

https://doi.org/10.34024/rnc.2008.v16.8650

Palavras-chave:

Anticonvulsivos, Inibidores Enzimáticos, Agentes GABAérgicos

Resumo

Farmacologistas, neurologistas e todos os clínicos devem considerar a eficácia, segurança e efeitos colaterais das drogas antiepilépticas quando determina qual melhor droga a ser dada ao paciente. A proposta deste trabalho é investigar o ácido valpróico com análise detalhada de diferentes artigos.

Downloads

Não há dados estatísticos.

Métricas

Carregando Métricas ...

Referências

Burton BS. On the propyl derivates and decomposition products of ethylacetate. Am Chem J 1882;3:385-95.

Meunier H, Carraz G, Meunier V, Eymard M. Propriétés pharmacodynamiques de l’ácide n-propylacétique. Thérapie1963:18:435-8.

Carraz G, Fau R, Chateau R, Bonnin J. Communication concerning 1st clinical test of the anticonvulsive activity of n-dipropylacetic acid (sodium salt). Ann Med Psychol (Paris) 1964;122:577-85.

Cukiert A. Epilepsias Generalizadas. São Paulo: Segmento Farma, 2006, 220p.

Dean JC. Valproate. In: Wylllie E (ed.). Treatment of epilepsy. Principles and Practice. Philadelphia: Lea&Febiger, 1993, 915-22.

Tung TC, Moreno RA.O papel do divalproato de sódio no tratamento dos transtornos do humor: eficácia, tolerabilidade e segurança. Rev Psiq Clin 2002;29(1):42-53.

Loscher W. Basic pharmacology of valproate: a review after 35 year of clinical use for the treatment of epilepsy. CNS Drugs 2002;16(10):669-94.

Perucca E. Pharmacological and therapeutic properties of Valproate: a summary after 35 years of clinical experience. CNS Drugs2002; 16(10):695-714.

Ichikawa J, Dai J, Meltzer HY. Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: Role of 5-HT (1 A) receptor agonism. Brain Res 2005;1049(2):182-90.

Patsalos PN, Peruca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2(6):347-56.

Kishore P, Rajani Kumar V, Satyanarayana V, Krishna DR. HPLC determination of Valproic Acid in human serum. Pharmazie 2003;58(6):378-80.

Schobben F, van der Kleijn E, Gabreels FJ. Pharmacokinetics of di-n-propylacetate in epileptic patients. Eur J Clin Pharmacol1975; 8(2):97-105.

King M. The new patient with a first seizure. Aust Fam Physician 2003;32(4):221-8.

Mory SB, Guerreiro CA, Li LM, Teixeira RA, Costa AL, Cardoso TA, et al. Idiopathic generalized epilepsies misdiagnosed as partial epilepsies. Arq Neuropsiquiatr 2002;60(3-B):788-96.

Bourgeois BF. Chronic management of seizures in the syndromes of idiopathic generalized epilepsy. Epilepsia 2003;44(suppl 2):27-32.

Lance JW, Anthony M. Sodium Valproate in the management of intractable epilepsy: comparison with clonazepam. Proc Aust Assoc Neurol 1975;12:55-60.

Alva Moncayo E, Ruuiz-Ruiz A. The value of Topiramate used with conventional schemes as an adjunctive therapy in the treatment of “Lennox Gastaut syndrome”. Rev Neurol 2003;36(5):453-7.

Singh MB, Kalita J, Misra UK. Landau Kleffner syndrome: electroclinical and etiopathogenic heterogeneity. Neurol India 2002;50(4):417-23.

Seki T. Treatment of West Syndrome: present and future perspectives. No To Hattatsu 1997;29(2):91-9.

Kochar DK, Jain N, Agarwal RP, Srivastava T, Agarwal P, Gupta S. Sodium Valproate in the management of painful neuropathy in type 2 diabetes a randomized placebo controlled study. Acta Neurol Scand 2002;106(5):248-52.

Cui SS, Yang CP, Bowen RC, Bai O, Li XM, Jiang W, Zhang X. Valproic acid enhances axonal regeneration and recovery of motor function after sciatic nerve axotomy in adult rats. Brain Res 2003;975(1-2):229-36.

Blaheta RA, Cinatl J Jr. Anti-tumor mechanisms of Valproate: a novel role for an old drug. Med Res Rev 2002;22(5): 492-511.

Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003;22(13):3411-20.

Yildirim E, Zhang Z, Uz T, Chen CQ, Manev R, Manev H.Valproate administration to mice increases histone acetylation and 5-lipoxygenase content in the hippocampus. Neurosci Lett 2003;345(2):141-3.

Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochem Pharmacol 2003;66(2):179-89.

Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003;2(7):404-9.

Cheng L, Lumb M, Polgar L, Mudge AW. How can the mood stabilizer VPA limit both mania and depression? Mol Cell Neurosci 2005;29(2):155-61.

Loy R, Tariot PN. Neuroprotective properties of valproate: potential benefit for AD and tauopathies. J Mol Neurosci 2002;19(3):303-7.

Green MW. The emergency management of headaches. Neurologist 2003;9(2):93-8.

Diener HCH. Pharmacological approaches to migraine. J Neural Transm Suppl 2003;(64):35-63.

Gallinat J, Stotz-IngenlathG, Lang UE, Hegerl U. Panic attacks, spike-wave activity, and limbic dysfunction. A case report. Pharmacopsychiatr 2003;36(3):123-6.

Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res 2003;62(3):237-44.

Peixoto MF, Abilio VC, Silva RH, Frussa-Filho R. Effects of Valproic acid on an animal model of tardive dyskinesia. Behav Brain Res 2003;142(1-2):229-33.

Majumdar S, Jones NS, McKerrow WS, Scadding G. The management of idiopathic olfactory hallucinations: a study of two patients. Laryngoscope 2003;113(5):879-81.

Esiobu N, Hoosein N. An assessment of the in vitro antimicrobial effects of two antiepileptic drugs- Sodium Valproate and phenytoin. Antonie Van Leeuwenhoek 2003;83(1):63-8.

Munts AG, Wennekes MJ, Koehler PJ. A child with peculiar movements: Sydenhan chorea. Ned Tijdschr Geneeskd 2003;147(6):257-60.

Mileusnic D, Donoghue ER, Lifschultz BD. Pathological case of the moth: sudden death in child as a result of pancreatitis during valproic acid therapy. Pediatr Pathol Mol Med 2002;21(5):477-84.

Jezequel AM, Bonazzi P, Novelli G, Venturini C, Orlandi F. Early structural and functional changes in liver of rats treated with a single dose of valproic acid. Hepatol 1984;4(6):1159-66.

Hirsch E, Genton P. Antiepileptic drug-induced pharmacodynamic aggravation of seizures: does valproate have a lower potential? CNS Drugs 2003;17(9):633-40.

Trinka E, Dilitz E, Unterberger I, Luef G, Deisenhammer F, Niedermuller U, et al. Non convulsive status epilepticus after replacement of valproate with lamotrigine. J Neurol 2002;249(10):1417-22.

Graziani G, Tentori L, Portarena I, Vergati M, Navarra P. Valproic Acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells. Endocrinol 2003;144(7):2822-8.

Van Gerpen JA. Drug–Induced parkinsonism. Neurologist 2002;8(6):363-70.

Pohlmann Eden B, Peters CN, Wennberg R, Dempfle CE. Valproate induces reversible factor XIII deficiency with risk of perioperative bleending. Acta Neurol Scand 2003;108(2):142-5.

Vesta KS, Medina PJ. Valproic Acid-induced neutropenia. Ann Pharmacother 2003;37(6):819-21.

Holmes LB. Teratogen-induced limb defects. Am J Med Genet 2002;112(3):297-303.

Gurvich N, Berman MG, Wittner BS, Gentleman RC, Klein PS, Green JB. Association of valproate- induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J 2005;19(9):1166-8.

Whitsel AI, Johnson CB, Forehand CJ. An in ovo chicken model to study the systemic and localized teratogenic effects of valproic acid. Teratology 2002;66(4):153-63.

Padmanabhan R, Shafiullah MM. Amelioration of sodium valproateinduced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. Congenit Anom (Kyoto) 2003;43(1):29-40.

Weber M, Dib M. Folic acid and prevention of anomalies of foetal neural tube closing in women treated for epilepsy. Rev Neurol (Paris) 2003;159(2):165-70.

Malm H, Kajantie E, Kivirikko S, Kaariainen H, Peippo M, Somer M. Valproate embryopathy in three sets of siblings :further proof of hereditary susceptibility. Neurology 2002;59(4):630-3.

Burneo JG, Limdi N, Kuzniecky RI, Knowlton RC, Mendez M, Lawn N, et al. Neurotoxicity following addition of intravenous valproate to lamotrigine therapy. Neurology 2003;60(12):1991-2.

Downloads

Publicado

2008-06-30

Como Citar

Fagundes, S. B. R. (2008). Ácido Valpróico:: revisão. Revista Neurociências, 16(2), 130–136. https://doi.org/10.34024/rnc.2008.v16.8650

Edição

Seção

Revisão de Literatura
Recebido: 2019-03-05
Publicado: 2008-06-30